Nova Neurology collaborates with the QEII Health Sciences Center and True North Clinical Research (located in the same building but independent) to engage in cutting edge research in area of Movement Disorders.
CURRENT RESEARCH STUDIES
Enroll-HD is a worldwide observational study for Huntington’s disease families. It will monitor how the disease appears and changes over time in different people, and is open to people who either have HD or are at-risk. Further information can be found at https://www.enroll-hd.org/
GENERATION-HD (ONGOING, RECRUITMENT CLOSED)
The GENERATION HD1 study will evaluate the efficacy and safety of RG6042 treatment given once every two months (bi-monthly) or once every four months (16-weeks) over a period of 25 months (approx. two years). Participants will be randomized to one of three treatment study arms: bi-monthly, every four months or placebo bi-monthly. This means for every two participants randomized to RG6042, one will receive placebo. The study is designed to test the potential effects of RG6042 compared to placebo. The study is “double-blind” meaning neither the participant nor his/her investigator or site staff will know which study arm the participant is assigned. Further information can be found at https://www.huntingtonsociety.ca/generation-hd1/
24-HOUR DAILY EXPOSURE OF CONTINUOUS SUBCUTANEOUS INFUSION OF ABBV-951 (RECRUITMENT CLOSED)
The purpose of this study is to assess the safety and tolerability of ABBV-951 in subjects with Parkinson's disease (PD).
PRIDOPIDINE OUTCOME ON FUNCTION IN HUNTINGTON DISEASE PATIENTS (PROOF-HD) (RECRUITMENT CLOSING)
Further information on this study will be posted when available.
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults (NOT YET RECRUITING)
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 690 patients across approximately 60 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group.